Prostate Cell News Volume 9.11 | Mar 23 2018

TOP STORY

Integrative Proteomics in Prostate Cancer Uncovers Robustness against Genomic and Transcriptomic Aberrations during Disease Progression

Investigators report high-throughput mass spectrometry on clinical tissue samples of benign prostatic hyperplasia, untreated primary prostate cancer and castration resistant prostate cancer (CRPC). Each sample group showed a distinct protein profile. By integrative analysis they showed that, especially in CRPC, gene copy number, DNA methylation, and RNA expression levels do not reliably predict proteomic changes. [Nat Commun] Full Article | Press Release

(Ranked by impact factor of the journal)

Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib

In prostate cancer cells and organoids, ALK F1174C expression enhanced growth and induced expression of the neuroendocrine marker neuron specific enolase. Alectinib was more effective than crizotinib in inhibiting ALK F1174C-expressing cell growth. [Clin Cancer Res] Abstract

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration Resistant Prostate Cancer (CRPC)

BET inhibitors reduced growth of prostate cancer cells and patient derived organoids with known androgen receptor (AR) mutations, AR amplification and AR-V7 expression. [Clin Cancer Res] Abstract

Orphan Nuclear Receptor TLX Contributes to Androgen Insensitivity in Castration-Resistant Prostate Cancer via Its Repression of Androgen Receptor Transcription

Investigators revealed that the TLX-induced resistance to androgen deprivation and anti-androgen was mediated through its direct suppression of androgen receptor gene transcription and signaling in both androgen-stimulated and -unstimulated prostate cancer cells. [Oncogene] Full Article

Tetrandrine (TET) Induces Death Receptors: Apo Trail R1 (DR4) and Apo Trail R2 (DR5) and Sensitizes Prostate Cancer Cells to TRAIL Induced Apoptosis

Scientists demonstrated that small-molecule TET potentially sensitizes previously resistant and mildly sensitive prostate cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)- induced apoptosis, and they do so by up-regulating mRNA expression and protein levels of death receptors DR4 and DR5. [Mol Cancer Ther] Abstract

Cholesterol Esterification Inhibition Suppresses Prostate Cancer Metastasis by Impairing the Wnt/β-Catenin Pathway

The authors observed an aberrant accumulation of cholesteryl ester in metastatic lesions using Raman spectroscopic analysis of lipid droplets in human prostate cancer patient tissues. Inhibition of cholesterol esterification in prostate cancer cells significantly suppresses the development and growth of metastatic cancer lesions in both orthotopic and intra-cardiac injection mouse models. [Mol Cancer Res] Abstract

Combining Immune Check-Point Blockade and Cryoablation in an Immunocompetent Hormone Sensitive Murine Model of Prostate Cancer

Treatment with anti-CTLA-4 antibody and cryoablation delayed the growth of the distant tumor by 14.8 days and decreased the mortality rate by factor of 4 when compared to cryoablation alone. [Prostate Cancer Prostatic Dis] Abstract

In Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer

By combining different approaches, including the integration of mRNA expression profiles, copy number alterations, and miRNA expression levels, scientists identified a gene signature of four genes overlapping with other published gene signatures and were able to distinguish, in silico, high Gleason-scored prostate cancer from normal human tissue, which was further enriched to 19 genes by gene co-expression analysis. [Int J Mol Sci] Full Article

Oncostatin M Induces Tumorigenic Properties in Non-Transformed Human Prostate Epithelial Cells, in Part through Activation of Signal Transducer and Activator of Transcription 3 (STAT3)

The authors showed that the interleukin-6-type cytokine oncostatin M induces cellular properties associated with tumorigenesis and disease progression in non-transformed human prostate epithelial cells, including morphological changes, epithelial-to-mesenchymal transition, enhanced migration and pro-invasive growth patterns. [Biochem Biophys Res Commun] Abstract

Long Non-Coding RNA FENDRR Reduces Prostate Cancer Malignancy by Competitively Binding miR-18a-5p with RUNX1

Investigators determined the expression of FENDRR and miR-18a-5p in prostate cancer (PCa) tissues and examined the regulatory mechanism in PCa cell lines. [Biomarkers] Abstract

Profiling Prostate Cancer Therapeutic Resistance

Scientists discuss the recent evidence on targeting the epithelial-mesenchymal-transition-mesenchymal epithelial transition dynamic interconversions to overcome therapeutic resistance in patients with recurrent therapeutically resistant prostate cancer. [Int J Mol Sci] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model

Veru Inc. announced the presentation of data from a preclinical study of VERU-111, a novel oral alpha and beta tubulin inhibitor, showing potent activity against paclitaxel sensitive and resistant prostate cancer models. [Press release from Veru Inc. (GlobeNewswire) discussing research presented at the 2018 European Association of Urology (EAU) 33^rd Annual Congress, Copenhagen] Press Release

UK Team to Lead Innovative European Prostate Cancer Program

The four-year Translational Research Network for Prostate Cancer aims to provide a multidisciplinary training program, integrating cancer biology and systems medicine to enable young researchers to become future leaders in cancer research. [University of Glasgow] Press Release

U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI^® (Enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Pfizer Inc. and Astellas Pharma Inc. announced that a sNDA for XTANDI^® has been accepted for filing and granted Priority Review designation by the FDA. [Pfizer Inc.] Press Release

NeoTract Announces Data from Large Real-World Study of UroLift^® System, Confirming Positive Results for Company’s Treatment for Enlarged Prostate

NeoTract announced the results from the first analysis of a retrospective registry of more than 800 UroLift^® System procedures performed at seven centers in North America, Europe and Australia. [NeoTract] Press Release

Merus and the Vall d’Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer

Merus N.V. and the Vall d’Hebron Institute of Oncology announced a strategic research collaboration to develop novel agents for therapeutic applications. [Merus N.V.] Press Release

US Science Agencies Set to Win Big in Budget Deal

Nearly all US science agencies would see their budgets grow in 2018, under a US$1.3-trillion spending deal announced. For the second year in a row, lawmakers in Congress seem set to ignore the steep cuts sought by President Donald Trump. [Nature News] Editorial

Expectations Are High for UKRI, the United Kingdom’s New £6 Billion Research Behemoth

Combine U.S. agencies akin to the National Institutes of Health, National Science Foundation, and National Endowment for the Humanities. Toss in some energy and innovation research and fuel it all with the largest boost in R&D spending in recent history. Then put one person in charge. [ScienceInsider] Editorial

HIV Researcher Is New Head of US Public-Health Agency

HIV researcher Robert Redfield will lead the Centers for Disease Control and Prevention, Secretary of Health and Human Services Alex Azar announced. [Nature News] Editorial

NEW Gordon Research Conferences: Cell Death
August 5-10, 2018
Newry, Maine, United States

Visit our events page to see a complete list of events in the community.

NEW Research Scientist – Prostate Cancer (Institute of Oncology Research)

Postdoctoral Position – Drug Development for Cancer (KU Leuven)

Principal Scientist – Translational Research (Medivir AB)

Senior Scientist – Target Discovery and Cancer Biology (Repare Therapeutics)

Postdoctoral Researcher – Cancer Biology (Duke University)

Postdoctoral Associate – Prostate Research (Baylor College of Medicine)

Research Fellowship – Prostate Cancer Pathology (Weill Cornell Medicine)

Postdoctoral Scientist Opportunities – Biomedical Research (Cedars-Sinai)

Postdoctoral Fellow – Prostate Disease Research (Henry M. Jackson Foundation for the Advancement of Military Medicine)

Postdoctoral Scientist – Cancer Research (Boehringer Ingelheim)

Postdoctoral Fellow – Cancer Biology (Johns Hopkins University)

Postdoctoral Research Fellow – Nuclear and Mitochondrial Mutagenesis in Carcinogenesis (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.